The simultaneous patent expiry of Ozempic in China and India has seen generic makers jump in. Low cost production in high volumes affords them an export opportunity as well as this drug is adopted in large numbers not just to treat diabetes but for weight-los…
Thats because the worlds two most-populous countries arent just consumers. They also have pharmaceutical firms that are capable of exploiting this moment to reshape the market for metabolic therapies… [+4323 chars]
